Business and Procurement Risks Arising from the Spread of COVID-19
First written in FY2020. 10 of 14 entries say "Materialised", first in FY2021-Q1. Latest entry: FY2024-Q2.
As One moved to the "Worse" side of this theme in 2020, the same year as the typical company in this theme.
The whole theme swung hardest in 2025: 5 of 16 companies on the "Worse" side.
3 other companies' latest entry also says "Materialised".
- FY2024-Q2MaterialisedAnnual report
「These measures enabled us to offset the demand adjustment for infection-control products associated with the change in COVID-19's legal classification.」
While demand adjustment for infection-control products associated with the transition to Category V actually occurred, it was offset by increased sales of long-tail products resulting from the expansion of products handled online and the broadening of the customer base. - FY2024-Q1MaterialisedAnnual report
「These measures enabled us to offset the demand adjustment associated with the easing of COVID-19's legal classification.」
Although demand adjustment associated with the easing of COVID-19's legal classification actually occurred, it was offset by increased sales of long-tail products resulting from the expansion of products handled online and the broadening of the customer base. - FY2023Change in risk assumptions following the reclassification of COVID-19Annual report
「It was announced that, from May 2023, COVID-19 would be classified as a Category V infectious disease under the Act on the Prevention of Infectious Diseases and Medical Care for Patients with Infectious Diseases. Concerns about restrictions on corporate activity and deterioration in employment conditions are expected to ease, while demand related to the pandemic from the government and local authorities is expected to decline.」
While the transition to Category V reduced concerns about restrictions on corporate activity, the assumptions changed to reflect an expected decline in infectious disease-related demand from the government and local authorities. - FY2023-Q3MaterialisedAnnual report
「Although the seventh and eighth waves followed the end of the sixth wave of COVID-19, economic activity continued to normalize.」
The seventh and eighth waves of COVID-19 continued in practice, sustaining demand for infection-control products such as protective gowns and high-performance masks for medical institutions. - FY2023-Q2MaterialisedAnnual report
「Demand for infection-control products such as medical gowns and aprons also increased during the seventh wave of COVID-19, when the number of positive cases reached a record high, contributing to higher revenue.」
The seventh wave of COVID-19 actually occurred, and demand for infection-control products such as medical gowns and aprons increased. - FY2023-Q1RestatedAnnual report
「There have been no material changes to the assumptions, including assumptions about the future spread of COVID-19 and the timing of its containment, described in the notes to the previous fiscal year's securities report under Additional Information (Accounting estimates associated with the spread of COVID-19).」
The Company stated that there had been no material changes to its accounting assumptions regarding the spread of COVID-19 and the timing of its containment. - FY2022-Q3MaterialisedAnnual report
「While progress in COVID-19 vaccinations raised expectations for an economic recovery, concerns remained over repeated waves of variant infections, global supply constraints caused by semiconductor shortages and higher resource prices, and cost-push inflation, and conditions remained volatile.」
The Company stated that the continuing spread of variants, semiconductor shortages and supply constraints caused by higher resource prices had brought business-environment uncertainty associated with the pandemic into the actual economic environment. - FY2022-Q2MaterialisedAnnual report
「In addition to repeated declarations of a state of emergency due to the spread of the Delta variant, semiconductor shortages and supply chain disruptions caused by the spread of infections in Southeast Asia led to production restrictions and other measures in the manufacturing sector, and conditions remained volatile.」
The spread of the Delta variant, repeated states of emergency, semiconductor shortages, and production restrictions and supply-chain disruptions caused by the spread of infections in Southeast Asia continued. - FY2022-Q1RestatedAnnual report
「There have been no material changes to the assumptions, including assumptions about the future spread of COVID-19 and the timing of its containment, described in the notes to the previous fiscal year's securities report under Additional Information (Accounting estimates associated with the spread of COVID-19).」
The Company stated that there had been no material changes from the previous fiscal year in its accounting assumptions regarding the spread of COVID-19 and the timing of its containment. - FY2021MaterialisedAnnual report
「However, the resurgence of infections came in waves, requiring responses including the reissuance of states of emergency and the implementation of priority preventive measures, and uncertainty about the outlook continued.」
The resurgence of infections, the reissuance of states of emergency, and shortages of equipment, supplies and personnel at medical facilities continued throughout the fiscal year. - FY2021-Q3MaterialisedAnnual report
「Although the Company experienced temporary product shortages, it strengthened procurement, including alternative products, and was able to supply infection-control products such as disposable wear and non-contact thermometers, as well as hygiene and testing-related products such as ATP meters, which were needed during the pandemic and in the new normal, not only to medical institutions but also to a range of other sectors.」
Temporary product shortages caused by the spread of infection actually occurred, while strengthened procurement, including alternative products, enabled the Company to supply infection-control, hygiene and testing-related products. - FY2021-Q2MaterialisedAnnual report
「Even while there were periods when production and research activities temporarily stagnated under the state of emergency」
The temporary stagnation of production and research activities under the state of emergency accompanying the spread of COVID-19 actually occurred. - FY2021-Q1MaterialisedAnnual report
「Even while production and research activities were temporarily stagnant under the state of emergency, demand for infection-prevention supplies and testing-related products increased sharply.」
During the first quarter, the temporary stagnation of production and research activities caused by the spread of COVID-19, shortages of supplies and personnel at medical facilities, and a sharp increase in demand for infection-prevention supplies and testing-related products actually occurred. - FY2020First statedAnnual report
「As seen in countries' responses to the spread of COVID-19, if an infectious disease for which no vaccine or specific treatment has been found were to spread and circumstances required the highest priority to be placed on preventing person-to-person contact, including through restrictions on going outdoors, corporate production and research activities could be restricted.」
The Company disclosed new risks involving restrictions on research and production activities due to the spread of infectious diseases, excess global demand, supplier production stoppages, and procurement and supply disruptions caused by export restrictions.